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1. Introduction 
Atopic dermatitis (AD) is a common, chronic fluctuating skin disease with prevalence in 
children (Williams, 2000; Williams & Wüthrich, 2000). The disease is an inflammatory skin 
disorder characterized by itching, and chronically relapsing course. Moreover, it also 
produces vulnerablity to surface infections caused by pathogenic bacteria, fungi and viruses. 
The most common skin infections in AD patients are caused by Staphylococcus aureus and 
herpes simplex virus (Ong & Leung, 2010). S. aureus is frequently detected in AD patients 
(Abeck & Mempel, 1998; Katsarou & Armenaka, 2011) and becomes an aggravating factor. 
In addition, toxins, such as staphylococcal enterotoxins and toxic shock syndrome toxin-1 
(McFadden et al., 1993; Bunikowski et al., 1999), generated from S. aureus may act as 
superantigens (Herz et al., 1999; Niebuhr et al., 2011; Yeung et al., 2011). In AD patients, 
viral infection is most often caused by herpes simplex virus (HSV) (Wollenberg et al., 2003). 
Eczema herpeticum is a potentially life-threatening disseminated HSV type 1 or type 2 
infection that occurs in 10% to 20% of AD patients (Peng et al., 2007). However, not only 
bacteria and viruses but also fungi, such as Malassezia species and Candida species, may play 
an important role as aggravation factors in AD patients. It has been reported that antifungal 
therapy is beneficial in the treatment of some AD patients (Bäck et al. 1995; Svejgaard et al. 
2004; Broberg et al. 1995; Mayser et al., 2006). In addition, several candidate Malassezia 
antigens have been implicated in the pathogenesis of AD. In this chapter, the involvement of 
fungi in the pathogenesis of AD is discussed. 
2. Fungi isolated from AD patients and treatment 
The genus Malassezia has recently been shown to consist of fifteen species based on the 
database of National Center for Biotechnology Information (2011), one lipid-independent 
species, M. pachydermatis and fourteen lipid-dependent species, M. sympodialis, M. furfur, M. 
globosa, M. obtusa, M. restricta, M. slooffiae, M. caprae, M. equine, M. dermatis, M. equi, M. 
japonica, M. nana, M. yamatoensis and M. cuniculi. Malassezia species have been recognized as 
members of the microbiological flora of human and animal skin. M. globosa and M. restricta 
are frequently isolated from the skin scales of human AD (Sugita et al., 2001; Tajima et al., 
2008; Kaga et al., 2009) and M. pachydermatis and M. nana are isolated from some animals 
(Aizawa et al., 2001; Hirai et al., 2004). Antifungal drugs, e.g. ketoconazole and itraconazole, 
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are used in AD patients with signs of a fungal infection (Sugita et al., 2005; Bäck et al., 1995). 
Antifungal therapy may remit the severity of AD by controlling these Malassezia yeasts. 
2.1 Related pathogenic fungi 
The yeasts of the genus Malassezia are members of the normal cutaneous flora. However, 
Malassezia colonization on the skin of AD patients shows a different pattern from that on 
healthy skin (Faergemann, 2002; Gupta et al., 2001; Nakabayashi et al., 2000; Sandström et 
al., 2005; Sugita et al., 2004, 2006) and may aggravate AD due to an allergic reaction, 
especially on the head and neck area in adults (Brehler & Luger, 2001; Broberg et al., 1992; 
Faergemann, 1999; Huang et al., 1995; Jensen-Jarolim et al., 1992; Lintu et al., 1997; Rokugo 
et al., 1990; Schmidt et al., 1997; Nakabayashi et al., 2000; Savolainen et al., 2001; Scalabrin et 
al., 1999). Scalabrin et al. (1999) measured total IgE and specific IgE to Malassezia furfur in 73 
AD patients. In the AD patients, specific IgE to M. furfur was observed more frequently in 
adults than children. The reaction of specific IgE to M. furfur was 132 times higher than that 
in healthy subjects. This result suggests that Malassezia yeast is associated with IgE-mediated 
skin inflammation in AD. 
Culture-dependent methods have been used for the detection of Malassezia species from AD 
patients (Nakabayashi et al., 2000; Sandström et al., 2005). However, in recent years, many 
researchers have attempted the detection of Malassezia species from AD patients by means of 
a molecular-based culture-independent method that is not affected by the isolation medium, 
sampling method, or incubation period. Table 1 summarizes the three major studies 
applying molecular based PCR assay to detect Malassezia species from AD patients and 
healthy subjects, indicating that the number of detected Malassetia species was similar to AD 
patients and healthy subjects (Sugita et al., 2001; Tajima et al., 2008; Kaga et al., 2009). 
 
Species 
Sugita et al. Tajima et al. Kaga et al. 
AD (32)* HS (18) AD (36) HS (30) AD (56) HS(32) 
M. globosa 93.8** 44.4 100 86.7 100 100 
M. restricta 87.5 61.1 97.2 83.3 100 100 
M. furfur 40.6 11.1 33.3 26.7 16.1 12.5 
M. sympodialis 40.6 50.0 58.3 36.7 65.2 62.5 
M. slooffiae 6.3 0 30.6 16.7 17.9 6.3 
M. obtuse 0 0 27.8 10 14.3 12.5 
M. pachydermatis 0 0 - - - - 
M. yamatoensis - - 13.9 6.7 21.4 15.6 
M. japonicum - - 33.3 10 10.7 12.5 
M. dermatis - - 30.6 30 37.5 34.4 
* Number of cases. ** Percentage of the number of patients. AD, atopic detmatitis; HS, healthy 
subjects. -, not detected. 
Table 1. Comparison of published research on Malassezia colonization in AD patients and 
healthy subjects. 
In both AD patients and healthy subjects, the predominant species were M. globosa and M. 
restricta. However, the study by Kaga et al. (2009), who applied real-time PCR to determine 
the number of rDNA copies of M. globosa and M. restricta, revealed that Malassezia 
colonization in severe AD patients was approximately two to five times higher than that in 
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other AD patients (mild and moderate) and healthy subjects. Since the species-specific DNA 
of M. globosa and M. restricta were frequently and massively detected, the two Malassezia 
species may be related to the severity of AD. 
Besides the Malassezia species, Candida species and dermatophytes are also involved in the 
pathogenesis of AD, and especially C. albicans may play a role in the alimentary canal of AD 
patients, becuase Candida species have been cultured more frequently from the gastrointestinal 
tract in AD patients than healthy subjects (Arzumanyan et al., 2000; Savolainen et al., 2003). 
Moreover, the possible involvement of dermatophytes, especially Trichophyton rubrum, in the 
inflammation in AD patients was reported (Klein et al., 1999). 
2.2 Control of fungi in AD patients 
Ketoconazole and itraconazole, azole antimycotics, have been the most frequently studied 
therapeutic agents for AD. The antimycotics showed strong antifungal activities against 
Malassezia species isolated from AD patients in vitro (Sugita et al. 2005). In clinical studies, 
ketoconazole and itraconazole have shown a significant therapeutic effect on AD patients. 
Bäck et al. (1995) assessed the efficacy of oral ketoconazole treatment on 20 AD patients 
using a positive radioallergosorbent test. The AD patients were treated with ketoconazole 
200 mg daily for 2 months and 200 mg twice a week for another 3 months. Of the 20 
patients, 18 completed the ketoconazole treatment regimen for 5 months and most patients 
showed a good to moderate response for ketoconazole 200 mg daily during the 2 months 
but no further improvement after the administration of ketoconazole 200 mg twice a week 
for another 3 months. Svejgaard et al. (2004) evaluated the efficacy of oral itraconazole in the 
treatment of AD patients with head and neck dermatitis in a randomized, double-blind, 
placebo-controlled study. The AD patients were treated daily with itraconazole 200 mg, 400 
mg or placebo for 7 days. The treatment with 200 mg and 400 mg of itraconazole exerted a 
remarkable therapeutic effect on AD patients. Therefore, the systemic antimycotic 
administration is expected to be highly effective in treating AD patients.  
Meanwhile, the application of topical antimycotics could decrease Malassezia colonization 
and the severity of eczematous lesions in AD patients. For instance, as reported by Broberg 
et al. (1995), the treatment of AD patients who had head and neck dermatitis with twice-
daily miconazole-hydrocortisone cream and twice weekly ketoconazole shampoo for 4 
weeks resulted in decreased Malassezia colonization although clinical scores were not greatly 
improved. In addition, they confirmed the effect of ciclopiroxolamine on AD patients with 
moderate to severe head and neck dermatitis, which is often difficult to be treated, in a 
double-blind, placebo-controlled study. 
3. Fungal infection in animals with AD 
Fungal infection in animals with AD has been reported mainly in canines and felines. For 
instance, Morris et al. (2002) reported that cell-mediated and humoral reactivities to M. 
pachydermatis contribute to the pathogenesis of AD in dogs but are not directly correlated. 
They investigated whether the potential cell-mediated immune response of atopic dogs to the 
yeast M. pachydermatis is correlated with the type-1 hypersensitivity (humoral) response of the 
same population of dogs. Atopic dogs with cytologic evidence of Malassezia dermatitis had an 
increased lymphocyte blastogenic response to crude M. pachydermatis extract, compared with 
clinically normal dogs and dogs with Malassezia otitis. The blastogenic responses in atopic 
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control dogs (without Malassezia dermatitis or otitis) did not differ significantly from those in 
atopic dogs with Malassezia dermatitis. No significant correlation was found between the 
lymphocyte blastogenic response and the type-1 hypersensitivity response to M. pachydermatis 
within any of the groups, suggesting that modification of the dysregulated immune response 
toward M. pachydermatis may assist in the reduction of pathologic changes associated with an 
AD phenotype in dogs. In another study, Chen et al. (2002) compared IgE responses to 
separated proteins of M. pachydermatis in atopic dogs with Malassezia dermatitis and clinically 
normal dogs. The results of their study showed that the majority of atopic dogs with Malassezia 
dermatitis have a greater IgE response than normal dogs, suggesting an IgE-mediated immune 
response may be clinically important in the pathogenesis of the disease. In felines, Malassezia 
spp. have been more frequently isolated from healthy ear canals and skin in feline leukaemia 
(FeLV)- or feline immunodeficiency virus (FIV)-infected cats than in those noninfected (Sierra 
et al., 2000). In addition, Malassezia spp. overgrowth has been described in feline localized 
benign exfoliative skin diseases, such as chin acne and the idiopathic facial dermatitis of 
Persian cats (Jazic et al., 2006; Bond et al., 2000). Based on these findings, Ordeix et al. (2007) 
conducted a multicentre, retrospective and descriptive study to document Malassezia spp. 
overgrowth in allergic cats. Their results suggested that Malassezia spp. overgrowth may 
represent a secondary cutaneous problem in allergic cats particularly in those with greasy 
adherent brownish scales on their skin. The favorable response to treatment with antifungal 
agent alone suggests that, as in dogs, Malassezia spp. may be partly responsible for both 
pruritus and cutaneous lesions in allergic cats. 
4. Mechanisms by which fungi act as an exacerbating factor for atopic 
dermatitis 
4.1 Antigen-specific inflammation caused via activation of antigen-specific T cells 
Allergy to fungi such as Candida spp. and Malassezia spp. has been implicated as an 
exacerbating or intractable factor in the symptoms of AD (Savolainen et al., 1993; Tanaka et 
al., 1994; Kitamura et al., 1997; Morita et al., 1999; Linder et al., 2000; Faergemann 2002; 
Kanda et al., 2002; Svejgaard et al., 2004). Candida spp. are indigenous fungi inhabiting the 
oral cavity, digestive tract and vagina. Healthy people are thought to acquire the Th1 type 
immunity against Candida spp. (Tanaka et al., 1994; Romani et al., 1995). For instance, the 
activation of Th1-type CD4+ cell induces phagocyte-dependent immunity, which apparently 
represents an important mechanism of anti-Candida resistance, and it was demonstrated that 
healthy subjects with a normal immune response show high peripheral blood lymphocyte 
proliferative responses as well as positive scarification patch tests to C. albicans antigen, 
suggesting the dominant presence of Thl type T cells specific to C. albicans antigen. It is well 
known that Thl clones secrete IL-2 and IFN-γ and preferentially induce delayed type 
hypersensitivity (Stout & Bottomly, 1989), while Th2 clones produce IL-4, IL-5 (Mosmann et 
al., 1986) and IL-10 (Fiorentino et al., 1989) and help to promote IgE production (Boom et al., 
1988; Killar et al., 1987). In AD patients, Th1-type immunity has been shown to shift to Th2-
type (Fig. 1) since the patients immediately react to skin testing using Candida-antigen 
(Tanaka et al., 1994; Kitamura et al., 1997), and Candida-specific IgE increases with the 
severity of the symptoms of AD (Tanaka et al., 1994). Specifically, AD patients displayed a 
significantly lower incidence of positive patch test reactions to C. albicans allergen than the 
healthy control subjects, and the patients with negative C. albicans patch tests tended to have 
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higher levels of total serum IgE including anti-C. albicans IgE antibody. In other words, the 
delayed-type hypersensitivity to C. albicans antigen, which is highly prevalent in atopics 
without dermatitis as well as non-atopics, was reduced in most of the AD patients. 
 
 
Fig. 1. Shift of Th1-type immunity to Th2-type immunity in allergic diseases including 
atopic dermatitis (AD). In healthy individuals, dendritic cells present fungal antigen to 
naive T cells which in turn differentiate to Th1 type cells, resulting in the cellular immune 
response. In AD patients, Th1-type immunity shifts to Th2-type immunity in which Th2 
clones produce IL-4, IL-5 and IL-10 and induce IgE production. 
The lipophilic fungus M. furfur indigenously inhabits the seborrheic region of the body, such 
as head, neck and upper part of the back. It was also reported that the fungus may be 
implicated in rosacea-like dermatitis and edematous erythema, which are chromic and 
intractable symptoms characteristic to the face with adult-type AD (Mukai et al., 1997), and 
that Malassezia-specific IgE level is high in the head and neck of AD patients (Bayrou et al., 
2005; Darabi et al., 2009). Regarding the 11 currently recognized Malassezia species as an 
exacerbating factor in AD, M. globosa and M. restricta are found to frequently colonize the 
skin of AD patients. For instance, specific IgE antibodies against eight Malassezia species (M. 
dermatitis, M. furfur, M. globosa, M. obtusa, M. pachydermatis, M. slooffiae, M. sympodialis, and 
M. restricta) in sera from AD patients were examined using an enzyme-linked 
immunosorbent assay, and it was found that the specific IgE value against M. restricta was 
greater than those against the other Malassezia species (Kato et al., 2006). 
4.2 Candida albicans gut colonization 
It has been hypothesized that excessive colonization by C. albicans in the gastrointestinal 
tract may constitute an aggravating factor in AD, but this remains controversial 
(Faergemann et al., 2002; Lacour et al., 2002; Nikkels & Pierard, 2003). To date, laboratory 
and clinical investigations have demonstrated that IgE mediated food allergy plays a 
pathogenic role in a subset of AD patients (Eigenmann et al., 1998; Lever et al., 1998; van 
Reijsen et al., 1998). Some reports have shown increased gastrointestinal permeability in 
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AD patients (Jackson et al., 1981; Majamaa et al., 1996; Pike et al., 1986). 
Hyperpermeability of the gastrointestinal mucosal barrier results in enhanced transport of 
intact and degraded antigens across the gastrointestinal mucosal barrier, which could 
induce food protein sensitization and food allergy in susceptible individuals (Farhadi et 
al., 2003) (Fig. 2). Yamaguchi et al. (2006) therefore hypothesized that gastrointestinal 
colonization by C albicans may be involved in aggravation of AD by affecting the mucosal 
barrier in a manner that results in increased permeation of food allergens and subsequent 
manifestation of a food allergy. Using mice, they examined whether gastrointestinal 
colonization by C. albicans contributes to the aggravation of AD. Candida colonization was 
establised by intragastric inoculation with C. albicans, and then mice were intragastrically 
administered ovalbumin every other day for nine weeks. As a result, ovalbumin specific 
IgG and IgE titres were higher in BALB/c mice with Candida colonization than in normal 
mice, suggesting that gastrointestinal permeation of ovalbumin was enhanced by 
colonization in the mice. Histological examination showed that colonization promoted 
infiltration and degranulation of mast cells.  
 
 
Fig. 2. Candida albicans gut colonization as an aggravating factor in atopic dermatitis. 
Excessive colonization by C. albicans in the gastrointestinal tract induces hyperpermeability 
of the gastrointestinal mucosal barrier, resulting in enhanced transport of intact and 
degraded antigens across the gastrointestinal mucosal barrier. This induces food protein 
sensitization and food allergy in susceptible individuals. 
Candida colonization did not enhance ovalbumin permeation in mast cell deficient W/Wv 
mice but did in congenic littermate control +/+ mice. Reconstitution of mast cells in W/Wv 
mice by transplantation of bone marrow-derived mast cells restored the ability to increase 
ovalbumin permeation in response to Candida colonization. These results suggest that 
gastrointestinal Candida colonization promotes sensitization against food antigens, at least 
partly due to mast cell-mediated hyperpermeability in the gastrointestinal mucosa of mice. 
To confirm that gut colonization of C. albicans aggravates atopic dermatitis, Sonoyama et al. 
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(2011) examined whether C. albicans gut colonization aggravates immune diseases in mice. 
Mice were inoculated intragastrically with C. albicans to establish chronic and latent C. 
albicans gut colonization. Allergic diarrhea was induced by repeated intragastric 
administration of ovalbumin in BALB/c mice. Contact hypersensitivity was evaluated by 
measuring ear swelling after topical application of 2, 4-dinitrofluorobenzene in NC/Nga 
mice, which are often used as a mouse model of AD (Jin et al., 2011; Orita et al., 2010). 
Arthritis was induced by intradermal injection of bovine type-II collagen emulsified with 
complete Freund's adjuvant in DBA/1J mice. C. albicans gut colonization increased the 
incidence of allergic diarrhea, which was accompanied by gut hyperpermeability, as well as 
increased infiltration of inflammatory cells in the colon. Contact hypersensitivity was also 
exacerbated by C. albicans gut colonization, as demonstrated by increased swelling, 
myeloperoxidase activity, and proinflammatory cytokines in ear auricles. Furthermore, C. 
albicans gut colonization promoted limb joint inflammation in collagen-induced arthritis in 
an animal model of rheumatoid arthritis (Setoguchi et al., 2010; Takagi et al., 2009). These 
findings suggest that C. albicans gut colonization in mice aggravates inflammation in allergic 
and autoimmune diseases, and evokes the necessity of investigating the pathogenic role of 
C. albicans gut colonization in immune diseases in humans. 
4.3 Skin barrier dysfunction 
Skin barrier dysfunction (Ogawa et al., 1993; Cork et al., 2006 & 2009; Elias et al., 2008; 
Palmer et al., 2006) has emerged as a critical driving force in the initiation and 
exacerbation of AD with a recent major breakthrough in the genetics of AD (O'Regan et 
al., 2009; Hudson et al., 2006; Brown SJ, McLean, 2009). For instance, as addressed by 
Ogawa et al. (1993), dryness of the skin is an important component of the atopic diathesis, 
thereby reflecting possible skin barrier dysfunction. When the two abnormalities, dry 
skin/barrier dysfunction and allergy/immunological dysfunction, are considered as the 
major underlying defects of AD, the wide range of clinical manifestations seen in AD can 
be more easily comprehended. A defect of the mucocutaneous barrier readily allows 
penetration of multiple antigens or haptens, which enhances allergic inflammation. On 
the other hand, an allergic inflammation derived from the immunological abnormalities 
damages barrier functions. This sequence cycle could answer the question as to why AD 
patients show IgE production against, and contact hypersensitivity to, various antigens or 
haptens. A set of protective/defensive functions generated in the epidermis is likely 
mediated by its unique differentiation end product, the stratum corneum (Elias 2005; Elias 
& Choi, 2005). Basically, a markedly increased transepidermal water loss and a markedly 
decreased water holding capacity of the stratum corneum were reported in AD patients 
(Watanabe et al., 1991). In addition, since the patients showed a higher transepidermal 
water loss following irritant exposure, the susceptibility to irritants in AD patients seemed 
to be closely related with a breakdown in the barrier function of the stratum corneum 
(Tupker et al., 1990). More recently, it has been proposed that AD is a multifactorial, 
heterogenous disease that arises as a result of the interaction between both environmental 
and genetic factors (Cork et al., 2009). Changes in at least three groups of genes encoding 
structural proteins, epidermal proteases, and protease inhibitors make AD patients prone 
to a defective epidermal barrier, resulting in increased risk of developing AD. Loss-of-
function mutations found within the FLG gene, which encodes the structural protein, 
filaggrin, could be the most significant genetic factor toward AD. In addition, enhanced 
protease activity and decreased synthesis of the lipid lamellae lead to exacerbated 
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breakdown of the epidermal barrier. It can be summarized that these functions include 
the permeability barrier, which prevents transcutaneous evaporative water loss, and an 
antimicrobial barrier, which simultaneously encourages colonization by nonpathogenic 
‘‘normal’’ flora (Elias, 2007). According to the report by Selander et al. (2009), 
approximately 50% of adult AD patients have allergen-specific IgE reactivity to the skin 
commensal yeast Malassezia spp. Due to the ruptured skin barrier in AD, it is likely that 
Malassezia come into contact with mast cells, which are known to be involved in AD. Since 
mast cells are located in the superficial dermis close to blood vessels, they are 
advantageously positioned to react with allergens diffusing through a ruptured 
epidermis. They are, therefore, recognized as key effector cells during IgE-associated Th2-
type immune responses (Galli et al., 2005), and cross-linking of the high-affinity IgE 
receptor (FcεRI) leads to release of potent inflammatory mediators (Turner & Kinet, 1999) 
such as histamine, proteases, chemotactic factors, cytokines, and metabolites of 
arachidonic acid (Henz et al., 2001). Mast cells have a wide variety of cell surface receptors 
that can interact directly with pathogens, including Toll-like receptors (TLRs), which are 
involved in innate immune recognition of invading microorganisms (Qiao et al., 2006). 
Fungal products such as zymosan can activate mast cells through TLR2 (Marshall, 2004). 
It has recently been reported that a synergistic activation between TLR2 and FcεRI can 
occur in mast cells, resulting in increased production of inflammatory cytokines (Qiao et 
al., 2006) (Fig. 3). Although both a defective epidermal permeability (Sugarman et al., 
2003; Seidenari & Giusti, 1995; Proksch et al., 2006; Chamlin et al., 2002; Eberlein-Konig et 
al., 2000) and a propensity to secondary infection (Boguniewicz et al., 2006; Baker, 2006) 
are well-recognized features of AD, these abnormalities have been widely assumed to 
reflect downstream consequences of a primary immunologic abnormality. 
 
 
Fig. 3. Skin barrier dysfunction in combination with skin indigenous Malassezia as an 
exacerbating factor in atopic dermatitis (AD). Due to the ruptured skin barrier in AD, it is 
likely that Malassezia and/or its products come into contact with mast cells which have a 
wide variety of cell surface receptors that interact directly with pathogens, including Toll-
like receptors (TLRs). A synergistic activation between TLR and IgE receptor (Fcε RI) can 
occur in mast cells, resulting in increased production of inflammatory cytokines. 
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5. Conclusion 
Well-known representative fungi that exacerbate AD are the resident fungi in the skin, 
Malassezia spp. such as M. furfur, M. globosa and M. restricta, and the resident fungus in the 
intestinal tract, C. albicans. The lipophilic fungus M. furfur indigenously inhabits the 
seborrheic region of the body such as the face, cervical part, and upper part of back. It was 
also reported that the fungus may be implicated in rosacea-like dermatitis and edematous 
erythema, which are chronic and intractable symptoms characteristic to the face in adult-
type AD. Regarding the underlying mechanism by which clinical manifestation of AD is 
affected in the presence of M. furfur, the following points have been proposed: 1) antigen-
specific inflammation caused via activation of antigen-specific T cells, and 2) dysfunction of 
skin barrier. A defect of skin barrier readily allows penetration of multiple antigens or 
haptens, which enhances allergic inflammation, and vice versa. That is, an allergic 
inflammation derived from the immunological abnormalities damages barrier functions. 
This sequence cycle could answer the question as to why AD patients show IgE production 
against, and contact hypersensitivity to, various antigens or haptens. Gut colonization of C. 
albicans is also regarded as the other fungal factor exacerbating AD by promoting 
sensitization against food antigens, at least partly due to mast cell-mediated 
hyperpermeability in the gastrointestinal mucosa. 
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